News
HVP – MaxCyte and Johns Hopkins University Announce Strategic Immuno-Oncology Collaboration to Advance CAR T-cell Therapies
April 21, 2015 02:00 AM – GAITHERSBURG, Md.–(BUSINESS WIRE)–MaxCyte® Inc., the pioneer in cell therapies using scalable, high-performance cell transfection systems, today announces a strategic research collaboration with Johns Hopkins University (JHU) to develop unique Chimeric Antigen Receptor (CAR) T-cell therapies, which harness patients’ own immune systems to combat cancers.
To view the full article please click here.